New study checks if VedAryo tames IBD Flare-Ups
NCT ID NCT07273760
First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study followed 150 people with inflammatory bowel disease (ulcerative colitis or Crohn's disease) who were given VedAryo (vedolizumab) to see if it helps control their condition and is safe. Participants received the drug by IV at the start, after 2 weeks, after 6 weeks, and then every 8 weeks for a year. The main goal was to see how many had fewer symptoms at 52 weeks, and researchers also tracked any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dr. Ali Beheshti-Namdar Clinic
Mashhad, Razavi Khorasan Province, Iran
-
Dr. Hamid Asadzadeh Aghdaei Clinic
Tehran, Iran
-
Dr. Hassan Vossoughinia Clinic
Mashhad, Razavi Khorasan Province, Iran
-
Dr. Mahtab Shabani Clinic
Tehran, Iran
-
Dr. Mohammad-Javad Kaviani Clinic
Shiraz, Fars, Iran
-
Dr. Naser Ebrahimi Daryani Clinic
Tehran, Iran
-
Gilan Gastroenterology and Hepatology Subspecialty Clinic
Rasht, Gilan Province, Iran
-
Imam Khomeini Hospital
Tehran, Iran
-
Mehr Specialty Clinic
Tehran, Iran
-
Professor Shahram Agah Gastroenterology, Hepatology, and Endoscopy Subspecialty Clinic
Tehran, Iran
-
Shariati Hospital
Tehran, Iran
-
Taleghani Hospital
Tehran, Iran
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vedolizumab (VedAryo)
What this could lead to
If successful, this study could confirm that VedAryo is a safe and effective option for controlling inflammatory bowel disease symptoms.
What could go wrong
This is an observational study with no comparison group, so results are less reliable. It only follows 150 people for 52 weeks, so long-term safety and effectiveness are not fully assessed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.